Upamostat (WX-671), a prodrug of WX-UK1, is an orally active serine protease inhibitor. Upamostat inhibits the urokinase-type plasminogen activator (uPA) system, blocking the plasminogen activation process mediated by it, thereby suppressing the invasion, migration and metastasis of tumor cells. Upamostat can be used in the research of metastatic breast cancer and locally advanced pancreatic cancer[1].
Molecular Weight:
629.81
Purity:
99.02
CAS Number:
[590368-25-5]
Formula:
C32H47N5O6S
Target:
PAI-1,Ser/Thr Protease
Application Notes:
MCE Product type: Reference compound1
* VAT and and shipping costs not included. Errors and price changes excepted
